National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark.
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005491.
Pancreatic ductal adenocarcinoma (PDAC) is associated with very poor survival, making it the third and fourth leading cause of all cancer-related deaths in the USA and European Union, respectively. The tumor microenvironment (TME) in PDAC is highly immunosuppressive and desmoplastic, which could explain the limited therapeutic effect of immunotherapy in PDAC. One of the key molecules that contributes to immunosuppression and fibrosis is transforming growth factor-β (TGFβ). The aim of this study was to target the immunosuppressive and fibrotic TME in PDAC using a novel immune modulatory vaccine with TGFβ-derived peptides in a murine model of pancreatic cancer.
C57BL/6 mice were subcutaneously inoculated with Pan02 PDAC cells. Mice were treated with TGFβ1-derived peptides (major histocompatibility complex (MHC)-I and MHC-II-restricted) adjuvanted with Montanide ISA 51VG. The presence of treatment-induced TGFβ-specific T cells was assessed by ELISpot (enzyme-linked immunospot). Changes in the immune infiltration and gene expression profile in tumor samples were characterized by flow cytometry, reverse transcription-quantitative PCR (RT-qPCR), and bulk RNA sequencing.
Treatment with immunogenic TGFβ-derived peptides was safe and controlled tumor growth in Pan02 tumor-bearing mice. Enlargement of tumor-draining lymph nodes in vaccinated mice positively correlated to the control of tumor growth. Analysis of immune infiltration and gene expression in Pan02 tumors revealed that TGFβ-derived peptide vaccine increased the infiltration of CD8 T cells and the intratumoral M1/M2 macrophage ratio, it increased the expression of genes involved in immune activation and immune response to tumors, and it reduced the expression of myofibroblast-like cancer-associated fibroblast (CAF)-related genes and genes encoding fibroblast-derived collagens. Finally, we confirmed that TGFβ-derived peptide vaccine actively modulated the TME, as the ability of T cells to proliferate was restored when exposed to tumor-conditioned media from vaccinated mice compared with media from untreated mice.
This study demonstrates the antitumor activity of TGFβ-derived multipeptide vaccination in a murine tumor model of PDAC. The data suggest that the vaccine targets immunosuppression and fibrosis in the TME by polarizing the cellular composition towards a more pro-inflammatory phenotype. Our findings support the feasibility and potential of TGFβ-derived peptide vaccination as a novel immunotherapeutic approach to target immunosuppression in the TME.
胰腺导管腺癌(PDAC)的生存率非常低,使其分别成为美国和欧盟癌症相关死亡的第三和第四大原因。PDAC 的肿瘤微环境(TME)高度免疫抑制和纤维化,这可以解释免疫疗法在 PDAC 中的治疗效果有限。导致免疫抑制和纤维化的关键分子之一是转化生长因子-β(TGFβ)。本研究旨在使用一种新型免疫调节疫苗靶向 PDAC 中的免疫抑制和纤维化 TME,该疫苗含有 TGFβ 衍生肽,佐剂为 Montanide ISA 51VG。
C57BL/6 小鼠皮下接种 Pan02 PDAC 细胞。用 TGFβ1 衍生肽(MHC-I 和 MHC-II 限制性)治疗小鼠,并用 Montanide ISA 51VG 佐剂。通过酶联免疫斑点(ELISpot)评估治疗诱导的 TGFβ 特异性 T 细胞的存在。通过流式细胞术、逆转录定量 PCR(RT-qPCR)和批量 RNA 测序来表征肿瘤样本中免疫浸润和基因表达谱的变化。
免疫原性 TGFβ 衍生肽的治疗是安全的,并控制了 Pan02 荷瘤小鼠的肿瘤生长。接种疫苗的小鼠肿瘤引流淋巴结的增大与肿瘤生长的控制呈正相关。对 Pan02 肿瘤的免疫浸润和基因表达分析表明,TGFβ 衍生肽疫苗增加了 CD8 T 细胞的浸润和肿瘤内 M1/M2 巨噬细胞的比例,增加了与免疫激活和肿瘤免疫反应相关的基因表达,降低了肌成纤维细胞样癌相关成纤维细胞(CAF)相关基因和编码成纤维细胞衍生胶原的基因的表达。最后,我们证实 TGFβ 衍生肽疫苗可主动调节 TME,因为与未处理的小鼠相比,暴露于来自接种疫苗的小鼠的肿瘤条件培养基的 T 细胞增殖能力得到恢复。
本研究证明了 TGFβ 衍生多肽疫苗在 PDAC 小鼠肿瘤模型中的抗肿瘤活性。数据表明,该疫苗通过将细胞组成向更具促炎表型极化来靶向 TME 中的免疫抑制和纤维化。我们的研究结果支持 TGFβ 衍生肽疫苗作为一种新型免疫治疗方法靶向 TME 中免疫抑制的可行性和潜力。